[18F]Fluorodeoxyglucose – positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy

Abstract Objective. The aim of this study was to evaluate the clinical use of [18F]fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in addition to conventional preoperative radiological investigations in a defined group of patients with high-risk muscle-invasive bladder cancer. Materials and methods. In total, 103 patients with high-risk muscle-invasive bladder cancer defined as stage T3/T4 disease or as stage T2 with hydronephrosis or high-risk histological features, who were provisionally scheduled to undergo cystectomy, were prospectively recruited to the study. The patients were referred to FDG-PET/CT in addition to standard preoperative investigation with computed tomography (CT). The final treatment decision was reached at a multidisciplinary conference based on all available information including the FDG-PET/CT findings. Results. Compared to CT alone, FDG-PET/CT provided more supplemental findings suggesting malignant manifestations in 48 (47%) of the 103 patients. The additional FDG-PET/CT findings led to an altered provisional treatment plan in 28 out of 103 patients (27%), detection of disseminated bladder cancer and subsequent cancellation of the initially intended cystectomy in 16 patients, and identification of disseminated disease and treatment with induction chemotherapy before radical cystectomy in 12 patients. Conclusions. Preoperative FDG-PET/CT changed the treatment plan for a considerable proportion (27%) of the present patients. Accordingly, such examination can potentially improve the preoperative staging of cystectomy patients with high-risk features, and may also reduce the number of futile operations in patients with advanced disease who are beyond cure.

[1]  P. Dasgupta,et al.  Role of fluorodeoxyglucose positron emission tomography (FDG PET)‐computed tomography (CT) in the staging of bladder cancer , 2014, BJU international.

[2]  W. Meinhardt,et al.  Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone , 2014, BJU international.

[3]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[4]  A. Scott,et al.  18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. , 2014, Urology.

[5]  H. G. van der Poel,et al.  Induction chemotherapy followed by surgery in node positive bladder cancer. , 2014, Urology.

[6]  S. Horenblas,et al.  Impact of 18F‐fluorodeoxyglucose (FDG)‐positron‐emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle , 2013, BJU international.

[7]  B. V. van Rhijn,et al.  FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer. , 2013, The Journal of urology.

[8]  G. Janetschek,et al.  Update on use of Enhanced Imaging to Optimize Lymphadenectomy in Patients Undergoing Minimally Invasive Surgery for Urothelial Cancer of the Bladder , 2013, Current Urology Reports.

[9]  Tetsuya Shindo,et al.  A role for preoperative systemic chemotherapy in node-positive upper tract urothelial carcinoma treated with radical nephroureterectomy. , 2012, Japanese journal of clinical oncology.

[10]  Ji-An Liang,et al.  Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. , 2012, European journal of radiology.

[11]  R. Wahlqvist,et al.  Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. , 2012, European urology.

[12]  R. Hautmann,et al.  Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. , 2012, European urology.

[13]  S. Minner,et al.  Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. , 2012, European urology.

[14]  C. Stief,et al.  Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node‐negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial , 2010, BJU international.

[15]  W. Meinhardt,et al.  Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  C. Dinney,et al.  The impact of variant histology on the outcome of bladder cancer treated with curative intent. , 2009, Urologic oncology.

[17]  P. Malmström WHY HAS THE SURVIVAL OF PATIENTS WITH BLADDER CANCER NOT IMPROVED? , 2008, BJU international.

[18]  Dalton A Anjos,et al.  18F-FDG PET/CT Delayed Images After Diuretic for Restaging Invasive Bladder Cancer , 2007, Journal of Nuclear Medicine.

[19]  J. Stein,et al.  Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure , 2006, World Journal of Urology.

[20]  L. Mortelmans,et al.  FDG-PET for preoperative staging of bladder cancer , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  Sten Nilsson,et al.  Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. , 2004, European urology.

[22]  R. Millikan,et al.  Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? , 2003, The Journal of urology.

[23]  P. Russo,et al.  Cystectomy for bladder cancer: a contemporary series. , 2001, The Journal of urology.

[24]  D. Bajorin,et al.  Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. , 2001, The Journal of urology.

[25]  N. Arikan,et al.  Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma. , 1996, British journal of urology.

[26]  R. Wahl,et al.  Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. , 1991, The Journal of urology.